Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Low-Dose PremPro Osteoporosis sNDA Filing Planned For June

Executive Summary

Wyeth-Ayerst will file a low-dose PremPro sNDA for osteoporosis by the end of June, North American President Joseph Mahady said during American Home Products' May 16 analyst meeting in New York City.
Advertisement

Related Content

Wyeth Low-Dose Prempro Approval Offers Message To Offset Safety Issues
Wyeth Low-Dose Prempro Approval Offers Message To Offset Safety Issues
Wyeth Premarin Plan For 2002: Stabilize Rxs Ahead Of Low-Dose Launch
Wyeth Premarin Plan For 2002: Stabilize Rxs Ahead Of Low-Dose Launch
Wyeth Premarin Biannual Price Increases To Boost "Cheap" 60[cents] Daily Cost
Wyeth Premarin Biannual Price Increases To Boost "Cheap" 60[cents] Daily Cost
Wyeth Enbrel Facility On Track For Third Quarter '02; CHF Research Dropped
Wyeth Enbrel Facility On Track For Third Quarter '02; CHF Research Dropped
Premarin
Premarin
Advertisement
UsernamePublicRestriction

Register

PS037889

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel